Skip to main content
Key Specialties
Anesthesiology Cardiology Dermatology Diabetology Endocrinology Gastroenterology General Medicine Geriatrics Hematology Infectious Diseases Internal Medicine Nephrology Neurology Obstetrics and Gynecology Oncology Ophthalmology Pediatrics Psychiatry Radiology Respiratory Medicine Rheumatology Surgery Urology
Congress Coverage
ASH 2024 Annual Meeting 2024 ESMO Congress 2024 ERS Congress 2024 EASD Congress 2024 ESC Congress 2024 EAN Congress 2024 ASCO Annual Meeting 2024 ACC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on adolescent vaping

LIVE: Wednesday 29th January, 18:00-19:30 CET

Growing numbers of young people are using e-cigarettes, despite warnings of respiratory effects and addiction. How can doctors tackle the epidemic, and what health effects should you prepare to manage in your clinics?
ADVANCED SEARCH
Log in
Top
Clinical Autonomic Research

28-09-2024 | Semaglutide | Letter to the Editor

Management of obesity in an individual with ROHHAD syndrome with semaglutide 2.4 mg/week: a case report

Authors: Jean-baptiste Bonnet, Clotilde Ramillon-Cury, Sarah Tournayre, Ariane Sultan, Antoine Avignon

Published in: Clinical Autonomic Research

Login to get access

Excerpt

Dear Editor, …
Literature
1.
Khaytin I, Victor AK, Barclay SF, Benson LA et al (2023) Rapid-onset obesity with hypothalamic dysfunction, hypoventilation, and autonomic dysregulation (ROHHAD): a collaborative review of the current understanding. Clin Auton Res 33(3):251–268CrossRefPubMed
2.
Barclay SF, Rand CM, Gray PA, Gibson WT et al (2016) Absence of mutations in HCRT, HCRTR1 and HCRTR2 in patients with ROHHAD. Respir Physiol Neurobiol 221:59–63CrossRefPubMed
3.
Patwari PP, Rand CM, Berry-Kravis EM, Ize-Ludlow D, Weese-Mayer DE (2011) Monozygotic twins discordant for ROHHAD phenotype. Pediatrics 128(3):e711–e715CrossRefPubMed
4.
Chow C, Fortier MV, Das L, Menon AP et al (2015) Rapid-onset obesity with hypothalamic dysfunction, hypoventilation, and autonomic dysregulation (ROHHAD) syndrome may have a hypothalamus-periaqueductal gray localization. Pediatr Neurol 52(5):521–525CrossRefPubMed
5.
Mandel-Brehm C, Benson LA, Tran B, Kung AF et al (2022) ZSCAN1 autoantibodies are associated with pediatric paraneoplastic ROHHAD. Ann Neurol 92(2):279–291CrossRefPubMedPubMedCentral
6.
Hawton KAC, Doffinger R, Ramanan AV, Langton Hewer SC et al (2022) Rituximab therapy in ROHHAD(NET) syndrome. J Pediatr Endocrinol Metab 35(8):1102–1106CrossRefPubMed
7.
Wilding JPH, Batterham RL, Calanna S, Davies M et al (2021) Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med 384(11):989–1002CrossRefPubMed
8.
Jalal Eldin AW, Tombayoglu D, Butz L, Affinati A et al (2019) Natural history of ROHHAD syndrome: development of severe insulin resistance and fatty liver disease over time. Clin Diabetes Endocrinol 5:9CrossRefPubMedPubMedCentral
9.
Newsome PN, Buchholtz K, Cusi K, Linder M et al (2021) A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis. N Engl J Med 384(12):1113–1124CrossRefPubMed
10.
Marso SP, Bain SC, Consoli A, Eliaschewitz FG et al (2016) Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 375(19):1834–1844CrossRefPubMed
11.
Diene G, Angulo M, Hale PM, Jepsen CH et al (2022) Liraglutide for weight management in children and adolescents with prader-willi syndrome and obesity. J Clin Endocrinol Metab 108(1):4–12CrossRefPubMedPubMedCentral
12.
Heiss CN, Mannerås-Holm L, Lee YS, Serrano-Lobo J et al (2021) The gut microbiota regulates hypothalamic inflammation and leptin sensitivity in Western diet-fed mice via a GLP-1R-dependent mechanism. Cell Rep 35(8):109163CrossRefPubMed
13.
Kelly AS, Arslanian S, Hesse D, Iversen AT et al (2023) Reducing BMI below the obesity threshold in adolescents treated with once-weekly subcutaneous semaglutide 2.4 mg. Obesity 31(8):2139–2149CrossRefPubMed
14.
Grozinsky-Glasberg S, Franchi G, Teng M, Leontiou CA et al (2008) Octreotide and the mTOR inhibitor RAD001 (everolimus) block proliferation and interact with the Akt-mTOR-p70S6K pathway in a neuro-endocrine tumour cell line. Neuroendocrinology 87(3):168–181CrossRefPubMed
15.
Rubino D, Abrahamsson N, Davies M, Hesse D et al (2021) effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA 325(14):1414–1425CrossRefPubMed
16.
Fontes MAP, Marins FR, Patel TA, de Paula CA et al (2023) Neurogenic background for emotional stress-associated hypertension. Curr Hypertens Rep 25(7):107–116CrossRefPubMedPubMedCentral
17.
18.
Metadata
Title
Management of obesity in an individual with ROHHAD syndrome with semaglutide 2.4 mg/week: a case report
Authors
Jean-baptiste Bonnet
Clotilde Ramillon-Cury
Sarah Tournayre
Ariane Sultan
Antoine Avignon
Publication date
28-09-2024
Publisher
Springer Berlin Heidelberg
Published in
Clinical Autonomic Research
Print ISSN: 0959-9851
Electronic ISSN: 1619-1560
DOI
https://doi.org/10.1007/s10286-024-01072-x